David Kendall, MD

New Capabilities

As of September 2026: Leading clinical development of glepaglutide

Zealand Pharma's Zeydovio is one step from market in Europe. On September 17, the European Medicines Agency's scientific committee recommended approving the twice-weekly injection for adults with short bowel syndrome.

Updated Sep 20